Vitor Silva
Overview
Explore the profile of Vitor Silva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paul N, Galasso C, Baker J, Silva V
Risk Anal
. 2025 Feb;
PMID: 40007147
According to recent Household Pulse Survey data, roughly 1.1% of households were displaced due to disasters in the United States in recent years. Although most households returned relatively quickly, 20%...
2.
Silva V, Joaquim J, Matos C
Int J Risk Saf Med
. 2025 Feb;
36(1):49-56.
PMID: 39973428
BackgroundThe safety of medicines is a critical public health concern that requires continuous monitoring and evaluation throughout a drug's lifecycle, including post-authorization. Over the past decade, Portugal has undergone significant...
3.
Silva V, Madeira R, Joaquim J, Matos C
Medicines (Basel)
. 2024 Nov;
11(8).
PMID: 39584970
In recent years, the off-label use of medications in sports has increased significantly, primarily driven by psychological and social factors. Athletes frequently misuse drugs without adequate medical supervision, relying on...
4.
Gustafsson M, Silva V, Valeiro C, Joaquim J, van Hunsel F, Matos C
Pharmaceuticals (Basel)
. 2024 Aug;
17(8).
PMID: 39204114
Opioids are the strongest analgesics available and are crucial in the treatment of acute and chronic pain. The line between these critical medications and how they are used beyond standard...
5.
Silva V, Matos C
Clin Transl Oncol
. 2024 Apr;
26(10):2431-2443.
PMID: 38658461
Introduction: Treatment of cancer has been improved with the discovery of biological drugs that act as immune checkpoint inhibitors. In 2017, FDA designated pembrolizumab, an immune checkpoint inhibitor employed in...
6.
Fernandes J, Grzonka J, Araujo G, Schulman A, Silva V, Rodrigues J, et al.
ACS Appl Mater Interfaces
. 2023 Dec;
16(1):1767-1778.
PMID: 38113456
Two-dimensional (2D) transition metal dichalcogenides (TMDCs) are highly promising nanomaterials for various electronic devices such as field-effect transistors, junction diodes, tunneling devices, and, more recently, memristors. 2D MoSe stands out...
7.
Matos D, Ramos J, Brandao A, Baeta A, Rodrigues I, Dos Santos I, et al.
Sci Total Environ
. 2023 Nov;
912:168664.
PMID: 37996016
In this study we found that endocrine disrupting chemicals (EDCs) were omnipresent in a tropical seabird community comprising diverse ecological guilds and distinct foraging and trophic preferences. Because EDCs tend...
8.
Matos D, Ramos J, Bessa F, Silva V, Rodrigues I, Antunes S, et al.
Sci Total Environ
. 2023 Jul;
898:165437.
PMID: 37437636
Oceans have been considered as an unlimited supply of goods and services, but resource extraction and waste disposal became ubiquitous and have been damaging the health of marine ecosystems. Finding...
9.
Ferreira G, Baptista V, Silva V, Veiga M, Minas G, Catarino S
IEEE Trans Biomed Eng
. 2023 Apr;
70(8):2318-2328.
PMID: 37022426
Objectives: Optical spectrophotometry has been explored to quantify Plasmodium falciparum malaria parasites at low parasitemia, with potential to overcome the limitations of detection in the current diagnostic methods. This work...
10.
Colmiais I, Silva V, Borme J, Alpuim P, Mendes P
Micromachines (Basel)
. 2023 Jan;
14(1).
PMID: 36677276
Graphene has unique properties that can be exploited for radiofrequency applications. Its characterization is key for the development of new graphene devices, circuits, and systems. Due to the two-dimensional nature...